BANBN Stock Chart & Stats
$1700.00
$0.00(0.00%)
At close: 4:00 PM EDT
$1700.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$1,510.54 - $1,745.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$133.28B
Enterprise Value$5.83K
Total Cash (Recent Filing)$51.57M
Total Debt (Recent Filing)$208.10M
Price to Earnings (P/E)41.9
Beta0.18
Next Earnings
Mar 04, 2027EPS Estimate
33.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.99
Shares Outstanding75,000,000
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio1.27
Price to Book (P/B)3.08
Price to Sales (P/S)6.46
P/FCF Ratio-93.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$1,790.11Price Target Upside5.30% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)49.85
Revenue Forecast (FY)$19.70B
Bulls Say, Bears Say
Bulls Say
Specialized Peptide And Oligonucleotide CDMO PlatformBachem operates in specialized, regulated peptide and oligonucleotide development and manufacturing, serving customers from process development through commercial production. This integrated capability can support recurring relationships and customer retention as drug programs advance into larger-scale supply.
Conservative Balance SheetVery low leverage gives Bachem meaningful financial resilience and reduces dependence on debt-funded operations. A growing equity base also provides flexibility to support capacity, development activity, or other strategic investment while limiting the burden of interest and refinancing obligations.
Steady Revenue Growth And Solid ProfitabilityMulti-year revenue expansion combined with a roughly 21% net margin indicates a resilient earnings model rather than growth without profitability. Continued demand for specialized manufacturing and biochemical products could support reinvestment and preserve earnings capacity over the next several quarters.
Bears Say
Persistent Negative Free Cash FlowNegative free cash flow over several years means reported earnings have not consistently translated into cash available after investment. This can constrain internally funded expansion, increase reliance on financing or working-capital release, and reduce flexibility if capital needs remain elevated.
Gradual Margin CompressionThe gradual decline in margins suggests that cost intensity, investment requirements, or business mix may be limiting operating leverage despite continued revenue growth. If this trend persists, additional sales may produce less incremental profit and reduce the durability of earnings expansion.
Moderating Revenue GrowthA slowdown after the earlier step-up indicates that the company’s growth trajectory has become less rapid, making future expansion more dependent on new programs, customer volumes, or successful scale-up. Moderation can lengthen the path to stronger operating leverage and earnings growth.
Bachem Holding AG News
BANBN FAQ
What was Bachem Holding AG Class B’s price range in the past 12 months?
Bachem Holding AG Class B lowest stock price was $1510.54 and its highest was $1745.00 in the past 12 months.
What is Bachem Holding AG Class B’s market cap?
Bachem Holding AG Class B’s market cap is $133.28B.
When is Bachem Holding AG Class B’s upcoming earnings report date?
Bachem Holding AG Class B’s upcoming earnings report date is Mar 04, 2027 which is in 159 days.
How were Bachem Holding AG Class B’s earnings last quarter?
Bachem Holding AG Class B released its earnings results on Jul 30, 2026. The company reported $14.13 earnings per share for the quarter, beating the consensus estimate of $9.87 by $4.26.
Is Bachem Holding AG Class B overvalued?
According to Wall Street analysts Bachem Holding AG Class B’s price is currently Undervalued.
Does Bachem Holding AG Class B pay dividends?
Bachem Holding AG Class B does not currently pay dividends.
What is Bachem Holding AG Class B’s EPS estimate?
Bachem Holding AG Class B’s EPS estimate is 33.22.
How many shares outstanding does Bachem Holding AG Class B have?
Bachem Holding AG Class B has 75,000,000 shares outstanding.
What happened to Bachem Holding AG Class B’s price movement after its last earnings report?
Bachem Holding AG Class B reported an EPS of $14.13 in its last earnings report, beating expectations of $9.87. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Bachem Holding AG Class B?
Currently, no hedge funds are holding shares in MX:BANBN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bachem Holding AG Class B
Bachem Holding AG serves pharmaceutical and biotechnology companies globally, providing products crucial for research, clinical development, and commercial use. The company's primary focus is on the design, manufacturing, and regulatory support for peptide active pharmaceutical ingredients (APIs), specifically targeting novel peptide and oligonucleotide chemical entities (NCEs). Additionally, Bachem offers commercially available NCEs and generic compounds. Its comprehensive service portfolio includes project management, quality assurance and regulatory guidance, analytical testing, production adhering to Good Manufacturing Practices (GMP), manufacturing for research purposes, and expertise in supply chain and vertical integration. Established in 1971, Bachem Holding AG is headquartered in Bubendorf, Switzerland, and functions as a subsidiary of Ingro Finanz AG.
BANBN Stock 12 Month Forecast
Average Price Target
$1,790.11
▲(5.30% Upside)